Scholars Central

PerspectivePublished 24 Jan 2023

Ocrelizumab for the onset of tumefactive multiple sclerosis

Authors: Chrysta Ellis

Journal of Neurology and Clinical Neuroscience

Volume 7 · Issue 1 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The course of Multiple Sclerosis (MS) is incredibly diverse. "Aggressive" disease is characterised by a relapsing history that rapidly worsens physical and cognitive dysfunction, frequently in spite of treatment. Presentation of the case: There is a lack of standardisation in the diagnostic and management of aggressive Multiple Sclerosis (MS). There are currently no definite reports of ocrelizumab being used to treat tumefactive, breakthrough diseases. A 34 years old Caucasian lady was hospitalised after experiencing nausea, vomiting, and slight gait ataxia. Multiple demyelinating lesions in the brain were identified using Magnetic Resonance Imaging (MRI), many of which were infratentorial and displayed tumefactive appearance and gadolinium enhancement.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Neurology and Clinical Neuroscience
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Chrysta Ellis”